Results 21 to 30 of about 2,247 (204)
New developments in the management of severe skin and deep skin structure infections – focus on tedizolid [PDF]
Therapeutics and Clinical Risk Management, 2015 Michael J Durkin,1 G Ralph Corey2,3 1Department of Medicine, Division of Infectious Diseases, Duke University, Durham, NC, USA; 2Department of Medicine, Duke Clinical Research Institute, Durham, NC, USA; 3Duke Global Health Institute, Durham ...
Durkin MJ, Corey GR
doaj +1 more source
Tedizolid – a new antibiotic to solve old problems: prospects for the treatment of complicated skin and soft tissue infections [PDF]
Амбулаторная хирургия, 2019 The work describes a new antibiotic from the oxazolidinone group – tedizolid. The results of the clinical studies have shown a high efficacy of tedizolid in complicated skin and soft tissue infections.
A. V. Rodin, O. I. Agafonov
doaj +1 more source
In Vitro Activity of Tedizolid, Dalbavancin, and Ceftobiprole Against Clostridium difficile
Frontiers in Microbiology, 2018 Background:Clostridium difficile (C. difficile) is a major nosocomial pathogen that colonizes in the human gut. Recently, the U.S. FDA approved three new antimicrobial agents against gram-positive bacteria: Tedizolid, Dalbavancin, and Ceftobiprole.
Dana Binyamin +9 more
doaj +2 more sources
Hospital Pharmacy, 2014 Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Dennis J, Cada +2 more
openaire +2 more sources
Safety and tolerability of tedizolid as oral treatment for bone and joint infections
Microbiology Spectrum, 2023 Bone and joint infections (BJIs) are common infections increasingly managed with oral therapy. However, there are limited safe oral options for many Gram-positive pathogens.
Loren G. Miller +10 more
doaj +1 more source
Journal of Global Antimicrobial Resistance, 2022 Objectives: The aim of this study is to compare the in vitro activity and minimal inhibitory concentration (MIC) distributions of tedizolid and linezolid against Mycobacterium avium complex (MAC) strains using a reference broth microdilution assay and a ...
Eduardo Marfil +3 more
doaj +1 more source
Tedizolid: new data and experiences for clinical practice [PDF]
Revista Española de Quimioterapia, 2021 The most relevant information on the clinical uses of tedizolid from studies published in the last 18 months is presented in this brief review. The most important data indicate better tolerance and safety profile of long-term therapeutic regimes in off-label indications, such as osteoarticular infections and those caused by mycobacteria. Its lower risk
Salavert Lleti, M +3 more
openaire +3 more sources
Journal of Pharmaceutical Health Care and Sciences, 2023 Background Tedizolid is a new oxazolidinone antibiotic with high potency for the treatment of infections caused by methicillin-resistant Staphylococcus aureus and other species.
Daisuke Negishi +5 more
doaj +1 more source
International Journal of Infectious Diseases, 2021 Objectives: The antimicrobial activity of tedizolid and comparators was evaluated against a large worldwide collection of Staphylococcus aureus and Streptococcus pneumoniae isolates recovered from patients with pneumonia.
Cecilia G. Carvalhaes +3 more
doaj +1 more source
The Effectiveness of Linezolid and Teicoplanin for Managing Infections After Burn Injuries: A Retrospective Study. [PDF]
Health Sci RepABSTRACT Background and Aims Gram‐positive infections in burn patients present significant treatment challenges. This study compared the efficacy and safety of linezolid vs. teicoplanin for managing such infections in a clinical setting. Methods We conducted a retrospective study involving 77 burn patients with confirmed Gram‐positive infections at ...
Zendehdel A +4 more
europepmc +2 more sources